This article was originally published in The Gray Sheet
Going public via initial public offering of 2 mil. shares of common stock at $12 per share. The Webster, Texas-based epilepsy device manufacturer plans to use proceeds from the sale for R&D efforts, expansion of sales and marketing activities and manufacturing capabilities, working capital and general corporate purposes. Morgan Stanley and Kidder, Peabody are underwriting.
You may also be interested in...
Informa Pharma Intelligence has officially launched the seventh Global Generics & Biosimilars Awards, which will take place in October 2020 in Milan, Italy.
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.